AllSight
Companies · FBRX · Pharmaceutical Preparations · Acquisition · Aug 27, 2026

Forte Biosciences completes argenx’s $2.2B buyout as Nasdaq exit begins

$2.2B acquisitionpriced in
$77/share cash deal completed; 87.13% tendered
Forte Biosciences, Inc. (FBRX) — what happened, in plain English, and what it means versus what the market expected.

The market already knew this was the expected endpoint. Forte had disclosed the merger agreement on July 26, 2026, and the $77-per-share tender offer began on August 6, so this filing confirms a scheduled transaction rather than introducing a new bid, price increase, or financing surprise. 〔0〕 〔1〕

Transaction detailFiling disclosure
Cash offer price$77.00 per share (Item 2.01)
Shares tendered, including Parent holdings87.13% of outstanding shares (Item 2.01)
Aggregate transaction fundingApproximately $2.2 billion, from Parent cash on hand (Item 2.01)
Closing dateAugust 27, 2026 (Item 2.01)

Execution was clean, but not unexpectedly so. The offer cleared its minimum-ownership condition, 87.13% of shares were tendered or already owned by Parent, and all remaining conditions were satisfied or waived. That removes closing risk, but the successful outcome was already embedded in the announced deal terms. 〔2〕

The filing ends Forte’s standalone public-company status. The merger made Forte a wholly owned subsidiary of argenx, while Nasdaq trading was suspended and delisting and deregistration steps were requested. 〔3〕 〔4〕

Management and governance now belong to the acquirer. All prior directors and officers departed at closing, replaced by Argenx’s merger-sub team, and Forte’s charter and bylaws were restated. 〔5〕

Net read: transaction completion at the already-known terms. This is a definitive acquisition close, not an incremental fundamental update; the appropriate scorecard is the factual event itself rather than a beat or miss versus expectations.

Read the original 8-K on SEC EDGAR ↗
All FBRX filings, decoded →
Related companies in Pharmaceutical Preparations
Latest across the market
BURLBurlington beats Q2 EPS, raises FY outlook—but flags Q3 profit declineMBUUMalibu Boats beats Q4 estimates as Saxdor lifts sales, but FY26 margins slideDINDine Brands director retires as board shrinks to nineTHFFFirst Financial adds Hickory Point for $111.3M, pitching 7% EPS accretionBBYBest Buy beats Q2 expectations as domestic demand surges and guidance risesDGDollar General beats Q2 estimates as tariff refunds lift margins and guidance risesBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.